Table 1. Effect of BIO 5192 on... | American Society of Hematology

Table 1.

Effect of BIO 5192 on relapsing-remitting EAE when administered during the preclinical, peak acute, and remission phases of disease

Disease stage at treatment initiation	Mean day of onset	On-treatment severity index	Posttreatment severity index	Posttreatment relapse rate	No. of mice with chronic disease (no. mice in group)
Preclinical
Vehicle	15.90 ± 1.58	0.82 ± 0.13	0.57 ± 0.23	1.00	2 (9)
BIO 5192	25.13 ± 1.56^*	0.40 ± 0.15	1.40 ± 0.29^*	0.60	5 (10)
Remission
Vehicle	14.55 ± 0.78	1.00 ± 0.18	1.41 ± 0.18	1.09	4 (11)
BIO 5192	13.82 ± 0.69	1.19 ± 0.21	2.23 ± 0.05^*	1.18	11 (11)^*
Acute phase
Vehicle	12.56 ± 0.34	1.03 ± 0.19	1.20 ± 0.26	1.33	4 (9)
BIO 5192	13.00 ± 0.29	0.36 ± 0.17^*	1.81 ± 0.16	1.22	5 (9)

Disease stage at treatment initiation	Mean day of onset	On-treatment severity index	Posttreatment severity index	Posttreatment relapse rate	No. of mice with chronic disease (no. mice in group)
Preclinical
Vehicle	15.90 ± 1.58	0.82 ± 0.13	0.57 ± 0.23	1.00	2 (9)
BIO 5192	25.13 ± 1.56^*	0.40 ± 0.15	1.40 ± 0.29^*	0.60	5 (10)
Remission
Vehicle	14.55 ± 0.78	1.00 ± 0.18	1.41 ± 0.18	1.09	4 (11)
BIO 5192	13.82 ± 0.69	1.19 ± 0.21	2.23 ± 0.05^*	1.18	11 (11)^*
Acute phase
Vehicle	12.56 ± 0.34	1.03 ± 0.19	1.20 ± 0.26	1.33	4 (9)
BIO 5192	13.00 ± 0.29	0.36 ± 0.17^*	1.81 ± 0.16	1.22	5 (9)

Data are ± SEM. ^*P < .05 versus vehicle-treated control value.